Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

8(57.1%)

Phase 1

4(28.6%)

Phase 3

2(14.3%)

14Total

Phase 2(8)

Phase 1(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT05970289Phase 2Active Not Recruiting

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Role: lead

NCT06650852Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Role: lead

NCT06057012Phase 2Completed

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

Role: lead

NCT06491563Phase 2Active Not Recruiting

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Role: lead

NCT04507269Phase 2Completed

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

Role: lead

NCT04518410Phase 2Completed

ACTIV-2: A Study for Outpatients With COVID-19

Role: collaborator

NCT04749368Phase 2Completed

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

Role: lead

NCT05780424Phase 3Completed

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)